Marco Exams automatically processes endoscopic biopsies, IHC for HER2/PD-L1 and MSI sequencing results in Gastric Cancer to generate differential diagnoses, prognostic stratification and therapeutic suggestions. The system transforms laboratory and pathology reports into structured, evidence-based clinical recommendations.
Some answers to questions we often receive
Marco Exams integrates endoscopic biopsies, IHC for HER2/PD-L1 and MSI sequencing results for Gastric Cancer, including immunohistochemistry, FISH, next-generation sequencing (NGS), liquid biopsy (ctDNA) and imaging results when available in structured format, generating integrated clinical interpretation of all results.
Yes. Marco Exams connects via standard APIs (HL7 FHIR, ASTM) with leading LIS and LIMS systems. The integration allows Gastric Cancer exam reports to flow automatically into Marco Exams, generating real-time clinical interpretation without manual intervention.
Yes. Marco Exams identifies Gastric Cancer result patterns requiring urgent clinical action — an acquired resistance mutation, a molecular result indicating ineligibility for a planned therapy, or an unexpected actionable alteration — and generates directed alerts to the treating physician.
Marco Exams has an interpretation engine trained on Gastric Cancer-specific biomarkers: HER2 IHC/FISH, PD-L1 CPS, MSI, FGFR2b and EBV. For each marker, the system knows positivity thresholds per international guidelines, current therapeutic implications and complementary testing recommendations when results are borderline or unexpected.
Marco Exams' evidence engine updates continuously with reference guidelines for Gastric Cancer and published clinical trial data. FDA and EMA approvals and NCCN/ESMO guideline changes are systematically incorporated into the interpretation engine.
Marco Exams generates structured reports in PDF or web format, designed for direct presentation at Gastric Cancer tumor boards. The report integrates all patient exam results, clinical interpretation, prognostic stratification and recommended therapeutic options with their evidence sources.
HER2 IHC 2+ reports in gastric cancer require FISH confirmation but this step is not always automatically triggered from the laboratory.